Cwm LLC Buys 8,180 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Cwm LLC boosted its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 247.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,483 shares of the biotechnology company’s stock after buying an additional 8,180 shares during the quarter. Cwm LLC’s holdings in Aurinia Pharmaceuticals were worth $84,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 7.1% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 75,787 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 5,043 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Aurinia Pharmaceuticals by 12.0% in the first quarter. BNP Paribas Financial Markets now owns 78,466 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 8,398 shares in the last quarter. Capstone Investment Advisors LLC bought a new position in Aurinia Pharmaceuticals in the first quarter worth $158,000. Nordea Investment Management AB boosted its stake in Aurinia Pharmaceuticals by 51.7% during the first quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company’s stock worth $1,552,000 after buying an additional 105,100 shares in the last quarter. Finally, GSA Capital Partners LLP increased its holdings in Aurinia Pharmaceuticals by 196.1% in the 1st quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock valued at $1,750,000 after buying an additional 231,260 shares during the period. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Stock Up 0.1 %

Shares of AUPH opened at $7.05 on Friday. The business’s 50 day simple moving average is $6.95 and its 200-day simple moving average is $5.94. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82. Aurinia Pharmaceuticals Inc. has a one year low of $4.71 and a one year high of $10.05. The company has a market capitalization of $1.01 billion, a P/E ratio of -20.73 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. The business had revenue of $57.10 million for the quarter, compared to analysts’ expectations of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. Aurinia Pharmaceuticals’s revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.08) earnings per share. As a group, sell-side analysts predict that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AUPH has been the topic of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, insider Scott Michael Habig sold 18,249 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the transaction, the insider now owns 456,338 shares of the company’s stock, valued at $2,423,154.78. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 4.30% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.